Core Insights - Treace Medical Concepts, Inc. announced positive four-year interim results from its ALIGN3D™ study, demonstrating the effectiveness of the Lapiplasty Procedure for bunion treatment [1][2][3] Company Overview - Treace Medical Concepts is focused on advancing surgical management standards for bunions and related midfoot deformities, with an estimated 1.1 million annual surgical candidates in the U.S. [5][6] - The company has developed the patented Lapiplasty 3D Bunion Correction System, which addresses the root cause of bunions by correcting deformities in three planes [6] Clinical Study Details - The ALIGN3D™ study is a multicenter, prospective clinical study evaluating the Lapiplasty Procedure's outcomes, with 173 patients enrolled across seven clinical sites [3] - Key findings from the study include: - Early return to protected weight-bearing at an average of 7.7 days and return to athletic shoes at 6.5 weeks [5] - Low radiographic recurrence rates of 0.8% for HVA>20° and 8.4% for HVA>15° at 48 months [5] - Significant improvements in pain and patient-reported outcomes, with an 81% improvement in pain and 89% improvement in walking/standing [5] Market Positioning - The publication of the ALIGN3D™ study results is expected to enhance the market differentiation of the Lapiplasty Procedure among surgeons and patients [2] - The company aims to expand its clinical evidence base and continue improving the standard of care for bunion surgery [2]

CVRx (CVRX) Q2 2025 Earnings Call August 04, 2025 04:30 PM ET Company ParticipantsMichael Vallie - Managing DirectorKevin Hykes - President, CEO & DirectorJared Oasheim - CFOJohn Young - Director - Healthcare Equity ResearchRohin Patel - Vice PresidentConference Call ParticipantsSamantha Munoz - Medtech Equity Research AnalystBrandon Vazquez - Research AnalystFrank Takkinen - Senior Research Analyst - Medical DeviceChase Knickerbocker - Senior Equity Research Analyst - HealthcareRoss Osborn - Director & Lea ...

Core Viewpoint - NeuroOne Medical Technologies Corporation is set to release its financial results for the fiscal third quarter ended June 30, 2025, on August 14, 2025, before market open [1] Financial Results Announcement - The company will host an investor conference call and webcast on August 14, 2025, at 8:30 a.m. Eastern time to discuss the financial results and provide a corporate update [2] - Participants can join the call using specific dial-in numbers and access codes provided [2] Call Playback Information - A playback of the conference call will be available until August 28, 2025, with specific numbers for U.S. and international listeners [3] Company Overview - NeuroOne is focused on developing minimally invasive and high-definition solutions for EEG recording, brain stimulation, and ablation for neurological disorders such as epilepsy, Parkinson's disease, and chronic pain [4] - The company may also explore applications in other areas including depression, mood disorders, and artificial intelligence [4]

Company Overview - STRATA Skin Sciences, Inc. is a medical technology company focused on developing, commercializing, and marketing innovative products for dermatologic conditions such as psoriasis, vitiligo, and acne [5] - The company's product offerings include the XTRAC excimer laser, VTRAC lamp systems, and the TheraClearX Acne Therapy System [5] Upcoming Financial Results - STRATA will report its second quarter 2025 financial results on August 13, 2025, after the market closes [1] - A conference call will be held on the same day at 4:30 p.m. ET to review the financial results and provide updates on corporate developments [2] Conference Call Details - Interested parties can listen to the conference call by dialing 1-866-524-3160 for domestic calls or 1-412-317-6760 for international calls, with a recommendation to join approximately 10 minutes prior to the start time [3] - A telephonic replay of the call will be available until August 20, 2025, and a webcast replay will be accessible approximately one hour after the live call until February 13, 2026 [4] Partnership Program - STRATA offers a unique Partnership Program that includes a fee per treatment cost structure instead of requiring equipment purchase, installation, and use [6] - The program provides on-site training for practice personnel, service and maintenance of equipment, dedicated account and customer service associates, and co-op advertising support [6]

Conference Call and Webcast at 8:30 AM Eastern Time Following the conclusion of the conference call, a replay will be available for 30 days on the investor relations section of the Company's website at pavmed.com. About PAVmed PAVmed Inc. is a diversified commercial-stage medical technology company operating in the medical device, diagnostics, and digital health sectors. Its subsidiary, Lucid Diagnostics (Nasdaq: LUCD), is a commercial-stage cancer prevention medical diagnostics company that markets the Eso ...

AI and back-office software driving growth; China biopharma licensing on track for record year SAN FRANCISCO, July 29, 2025 /PRNewswire/ -- Despite a decline in overall fundraising, which is on track for the lowest amount closed in more than a decade, AI-related deal activity remains a bright spot for the healthcare sector, according to the latest report from Silicon Valley Bank (SVB), a division of First Citizens Bank. Over the last three years, all healthcare sectors saw strong growth in AI deal activity ...

Strategic Acquisition Positions Branded Legacy to Enter the Growing Naloxone and Vaccine Markets, Enhancing Shareholder Value; Leadership Transition Planned with Amin Janmohamed as New CEO and Chairman MELBOURNE, Fla., July 29, 2025 (GLOBE NEWSWIRE) -- via IBN -- Branded Legacy, Inc. (OTC: BLEG), a diversified holdings company focused on innovative health and wellness solutions, today announced the execution of a non-binding Letter of Intent (LOI) to acquire Bio-Legacy Evaluative Group, a pioneering health ...

Core Viewpoint - The Ensign Group, Inc. (ENSG) experienced an 8.9% increase in shares on July 25, driven by strong revenue growth in its Skilled Services segment, improved occupancy rates, and solid rental revenue growth, despite elevated expenses impacting overall profitability [1] Financial Performance - ENSG reported second-quarter 2025 adjusted EPS of $1.59, exceeding the Zacks Consensus Estimate by 3.3% and reflecting a 20.5% year-over-year improvement [2][8] - Operating revenues rose 18.5% year over year to $1.2 billion, surpassing the consensus mark by 1.8% [2][8] - Adjusted net income for the quarter was $93.3 million, a 22.1% increase year over year [3] Segment Performance - Skilled Services segment revenues reached $1.17 billion, growing 18.4% year over year, slightly above estimates [4] - Rental revenues increased by 34.7% year over year to $31.5 million, supported by buyouts [5] Expense and Cash Flow Analysis - Total expenses rose 18.3% year over year to $1.12 billion, exceeding estimates [3] - Cash and cash equivalents at the end of Q2 were $364 million, down 21.7% from the end of 2024 [6] - Net cash from operations for the first half of 2025 was $228 million, more than doubling year over year [7] Capital Deployment - The company repurchased shares worth $20 million and paid dividends totaling $7.2 million in the first half of 2025 [9] 2025 Outlook - Revenue guidance for 2025 has been raised to between $4.99 billion and $5.02 billion, indicating a 17.5% improvement from 2024 [10] - Adjusted EPS is now projected to be between $6.34 and $6.46 for 2025, reflecting a 16.4% growth from the previous year [10]

Company Overview - TransMedics Inc. (NASDAQ: TMDX) is involved in the design, manufacturing, and selling of organ care systems (OCS) [1] - The stock price experienced a significant increase of 53% from April 23 to its interim high on June 11, followed by a decline of 25%, bringing the current price to $108 [1] Stock Performance - The stock rose to an interim high on June 11, indicating strong market interest and performance during that period [1] - The subsequent decline of 25% suggests volatility and potential market corrections following the peak [1]

Core Insights - Integer Holdings Corporation reported strong financial performance in Q2 2025, with sales increasing by 11%, adjusted operating income rising by 15%, and adjusted EPS growing by 19% compared to Q2 2024. The company has raised its full-year 2025 profit outlook midpoint, expecting adjusted operating income growth of 12% to 16% and adjusted EPS growth of 18% to 23% [1][4]. Financial Performance - Q2 2025 sales reached $476 million, reflecting an 11% increase, with organic growth also at 11% [4][12]. - GAAP operating income increased by $5 million to $59 million, a 9% rise, while non-GAAP adjusted operating income rose by $10 million to $81 million, marking a 15% increase [4][31]. - GAAP income from continuing operations grew by $6 million to $37 million, a 19% increase, and non-GAAP adjusted net income increased by $10 million to $55 million, a 23% rise [4][31]. - Adjusted EBITDA increased by $9 million to $99 million, a 10% increase [4][31]. Product Line Performance - Cardio & Vascular sales surged by 24% in Q2 2025 compared to Q2 2024, driven by new product launches and strong customer demand [5]. - Cardiac Rhythm Management & Neuromodulation sales saw a modest increase of 2%, attributed to growth in emerging neuromodulation customers and normalized cardiac rhythm management growth [5]. - Sales in Other Markets decreased by 38%, primarily due to the planned exit from the portable medical market [5]. 2025 Outlook - The company anticipates full-year sales between $1.850 billion and $1.876 billion, representing an 8% to 9% increase from the prior year [3]. - Adjusted operating income is projected to be between $319 million and $331 million, reflecting a growth of 12% to 16% [3]. - Adjusted EPS is expected to range from $6.25 to $6.51, indicating an increase of 18% to 23% [3]. Debt and Cash Flow - Total debt increased by $212 million to $1.202 billion, with a leverage ratio of 3.2 times adjusted EBITDA as of June 27, 2025 [4][28]. - Cash flow from operating activities is projected to be between $235 million and $255 million, a 15% to 24% increase [3].